Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 19/20 | 0.55 |
| ▸ | HTR1D | P28221 | 16/20 | 0.55 |
| ▸ | HTR1B | P28222 | 16/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777163 | 0.89 | HTR1A (0.42) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL6111878 | 0.86 | KCNH2 (0.59) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL3774520 | 0.86 | KCNH2 (0.59) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL3779177 | 0.85 | KCNH2 (0.42) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL3780005 | 0.84 | KCNH2 (0.56) | HTR1ASLC6A4KCNH2 | |
| SCHEMBL3779227 | 0.84 | KCNH2 (0.51) | HTR1ASLC6A4KCNH2 | |
| SCHEMBL5433187 | 0.82 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL3782147 | 0.82 | KCNH2 (0.59) | HTR1AHTR1DHTR1BDRD2KCNH2 | |
| SCHEMBL3774422 | 0.82 | KCNH2 (0.48) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL3781197 | 0.82 | KCNH2 (0.47) | HTR1AHTR1DHTR1BSLC6A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-1943222-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | HTR1A 2919/4885HTR1D 3407/4885HTR1B 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.